These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 11575182

  • 1. [Where are quinolones going? New agents in development].
    Holzgrabe U.
    Pharm Unserer Zeit; 2001; 30(5):446-8. PubMed ID: 11575182
    [No Abstract] [Full Text] [Related]

  • 2. Update on cross-resistance of fluoroquinolones.
    Garau J.
    Int J Clin Pract Suppl; 2000 Dec; (115):94-8. PubMed ID: 11219309
    [No Abstract] [Full Text] [Related]

  • 3. [Recent development in quinolone compounds antitumor quinolones].
    Yang YS, Zhao SR, Ji RY, Chen KX.
    Yao Xue Xue Bao; 1998 Dec; 33(2):157-60. PubMed ID: 11938953
    [No Abstract] [Full Text] [Related]

  • 4. Mode of action of new quinolones: the inhibitory activity on DNA gyrase.
    Sato K, Hoshino K, Mitsuhashi S.
    Prog Drug Res; 1992 Dec; 38():121-32. PubMed ID: 1319080
    [No Abstract] [Full Text] [Related]

  • 5. Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
    Inagaki H, Takahashi H, Takemura M.
    Bioorg Med Chem Lett; 2004 Oct 18; 14(20):5193-8. PubMed ID: 15380226
    [Abstract] [Full Text] [Related]

  • 6. [New quinolones, current therapies].
    Auckenthaler R.
    Schweiz Rundsch Med Prax; 1988 Nov 08; 77(45):1217-8. PubMed ID: 2847274
    [No Abstract] [Full Text] [Related]

  • 7. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
    Ruiz J.
    J Antimicrob Chemother; 2003 May 08; 51(5):1109-17. PubMed ID: 12697644
    [Abstract] [Full Text] [Related]

  • 8. [The evolution of quinolone: from nalidixic acid to the quinolones of the third generation].
    Petersen U.
    Pharm Unserer Zeit; 2001 May 08; 30(5):376-81. PubMed ID: 11575173
    [No Abstract] [Full Text] [Related]

  • 9. Quinolones in 2005: an update.
    Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM.
    Clin Microbiol Infect; 2005 Apr 08; 11(4):256-80. PubMed ID: 15760423
    [Abstract] [Full Text] [Related]

  • 10. [How well do gyrase inhibitors work? The pharmacokinetics of quinolones].
    Sörgel F, Bulitta J, Kinzig-Schippers M.
    Pharm Unserer Zeit; 2001 Apr 08; 30(5):418-27. PubMed ID: 11575179
    [No Abstract] [Full Text] [Related]

  • 11. [Quinolones in the environment: biological breakdown of gyrase inhibitors].
    Wetzstein HG.
    Pharm Unserer Zeit; 2001 Apr 08; 30(5):450-7. PubMed ID: 11575183
    [No Abstract] [Full Text] [Related]

  • 12. [New quinolones].
    Kakeya H, Fukushima K, Saito A.
    Nihon Rinsho; 2007 Feb 28; 65 Suppl 2 Pt. 1():542-8. PubMed ID: 17455678
    [No Abstract] [Full Text] [Related]

  • 13. [How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist].
    Schurz JK.
    Pharm Unserer Zeit; 2001 Feb 28; 30(5):400-5. PubMed ID: 11575176
    [No Abstract] [Full Text] [Related]

  • 14. [Quinolones: confirmations and promises].
    De Marino V, Marino A.
    Clin Ter; 1990 Jan 15; 132(1):3-11. PubMed ID: 2139369
    [Abstract] [Full Text] [Related]

  • 15. [Mechanisms of bacterial resistance to quinolones].
    Taléns-Visconti R, Garrigues TM, Cantón E.
    Rev Esp Quimioter; 2002 Mar 15; 15(1):25-31. PubMed ID: 12582434
    [Abstract] [Full Text] [Related]

  • 16. [1,2,3]Triazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains.
    Carta A, Palomba M, Paglietti G, Molicotti P, Paglietti B, Cannas S, Zanetti S.
    Bioorg Med Chem Lett; 2007 Sep 01; 17(17):4791-4. PubMed ID: 17604166
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of resistance to quinolones.
    Hirai K, Mitsuhashi S.
    Prog Drug Res; 1992 Sep 01; 38():107-20. PubMed ID: 1609109
    [No Abstract] [Full Text] [Related]

  • 18. Framing the threat of resistance to quinolones in pharmacologic terms.
    Ambrose PG.
    Manag Care Interface; 2005 Apr 01; Suppl():4-6. PubMed ID: 15889780
    [No Abstract] [Full Text] [Related]

  • 19. Increasing incidence of quinolone-resistant E. coli from urinary cultures in Ankara-Pursaklar region.
    Tekin O, Catal F, Ibýk B, Açýkgöz ZC.
    Int J Antimicrob Agents; 2004 Apr 01; 23(4):416-7. PubMed ID: 15081097
    [No Abstract] [Full Text] [Related]

  • 20. In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone.
    Jones RN.
    J Chemother; 1989 Jul 01; 1(4 Suppl):165-7. PubMed ID: 16312353
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.